Streetbeat News

Regulatory

META

SNAP

A new GOP-led bill, the Take It Down Act, aims to hold social media platforms like Meta's Facebook, Instagram, and Elon Musk's X accountable for removing deepfake pornographic images within 48 hours of a valid request. The bill, sponsored by Sen. Ted Cruz, seeks to protect victims by mandating the removal of such images and any copies. The Federal Trade Commission will enforce these rules.

Portfolio Pulse from Benzinga Neuro

June 18, 2024 | 12:12 pm

MRK

PFE

The FDA has approved Merck's Capvaxive, the first pneumococcal conjugate vaccine designed for adults, covering 21 strains of bacteria. This approval is significant as it offers broader protection compared to Pfizer's Prevnar 20. Additionally, the FDA approved Merck's Keytruda for a new endometrial carcinoma indication.

Portfolio Pulse from Vandana Singh

June 18, 2024 | 12:05 pm

ERAS

Erasca, Inc. (NASDAQ:ERAS) has initiated the SEACRAFT-2 Phase 3 trial to evaluate the combination of naporafenib and trametinib in patients with NRAS-mutant melanoma. Naporafenib, a pan-RAF inhibitor, has shown favorable results in earlier trials and is being developed for multiple RAS/MAPK pathway-driven tumors. The trial's first stage results are expected in 2025.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 12:05 pm

AEMD

Aethlon Medical has received full ethics approval to conduct a clinical trial for its Hemopurifier in cancer patients with solid tumors unresponsive to anti-PD-1 therapy. This approval marks a significant milestone for the company in advancing its medical technology.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 12:05 pm

LGND

The FDA has approved CAPVAXIVE, the sixth product utilizing Pfenex Expression Technology. Ligand Pharmaceuticals (LGND) is entitled to royalties on global sales.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 12:03 pm

GOOG

GOOGL

Google's new FCC filing hints at a potential upgrade for the Nest Thermostat, featuring Wi-Fi, Bluetooth, and 60GHz radar. This could be a successor to the high-end Nest Learning Thermostat or a refresh of the entry-level model.

Portfolio Pulse from Ananya Gairola

June 18, 2024 | 11:52 am

MRK

Merck shares are trading higher after the FDA approved CAPVAXIVE for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:39 am

BBIO

BridgeBio Pharma has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 for Limb-girdle Muscular Dystrophy Type 2I/R9, with top-line results expected in 2025. The company is considering pursuing Accelerated Approval for BBP-418 following recent interactions with the FDA.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:36 am

PHIO

Phio Pharmaceuticals has been granted a patent in South Korea for its Intasyl compound, which targets photo-aging in skin care.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:34 am

SYRE

Spyre Therapeutics has started dosing healthy volunteers in its first clinical trial of SPY001 for Inflammatory Bowel Disease. Interim pharmacokinetic and safety data are expected by the end of 2024. SPY002 is set to begin first-in-human studies in the second half of 2024. All three next-generation antibodies are on track to be in the clinic within 12 months.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:33 am